These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30008894)

  • 41. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
    Ressing ME; de Jong JH; Brandt RM; Drijfhout JW; Benckhuijsen WE; Schreuder GM; Offringa R; Kast WM; Melief CJ
    Eur J Immunol; 1999 Apr; 29(4):1292-303. PubMed ID: 10229097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
    Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
    Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
    Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
    J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
    Evans M; Borysiewicz LK; Evans AS; Rowe M; Jones M; Gileadi U; Cerundolo V; Man S
    J Immunol; 2001 Nov; 167(9):5420-8. PubMed ID: 11673561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.
    Kim KH; Dishongh R; Santin AD; Cannon MJ; Bellone S; Nakagawa M
    Cancer Immun; 2006 Jun; 6():9. PubMed ID: 16808432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
    Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2.
    Kast WM; Brandt RM; Drijfhout JW; Melief CJ
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):115-20. PubMed ID: 7506573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Epitopic multiple antigen peptide from α-fetoprotein elicit antitumor immune response in vitro and ex vivo].
    Fan ZJ; Zhang SR
    Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1138-42. PubMed ID: 22781777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic variability and oncogenic risk association of human papillomavirus type 58 E6 and E7 genes in Taizhou area, China.
    Yu JH; Shi WW; Zhou MY; Liu JM; Han QY; Xu HH
    Gene; 2019 Feb; 686():171-176. PubMed ID: 30471332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice.
    McCarthy C; Youde SJ; Man S
    Int J Cancer; 2006 May; 118(10):2514-21. PubMed ID: 16353149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
    Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
    Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer.
    Kim S; Chung HW; Lee KR; Lim JB
    J Transl Med; 2014 Aug; 12():229. PubMed ID: 25141788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
    Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
    Front Immunol; 2018; 9():3000. PubMed ID: 30619353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif.
    Tarpey I; Stacey S; Hickling J; Birley HD; Renton A; McIndoe A; Davies DH
    Immunology; 1994 Feb; 81(2):222-7. PubMed ID: 8157270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.